Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Not applicable

Efficacy of Laser Acupuncture on Carpal Tunnel Syndrome Following Hand Flexor Tendon Repair

NCT07014774 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2025-06-15
Last updated
2025-06-11

Condition(s) studied

Laser AcupunctureFlexor Tendon RepairHand SurgeryCarpal Tunnel Syndrome (CTS)

Investigational drug(s) / intervention(s)

Laser acupunctureTraditional Therapy

Laser acupuncture: Laser acupuncture is a modern, non-invasive approach to acupuncture that uses low-level laser therapy (LLLT) instead of traditional needles to stimulate acupuncture points. This technique combines the principles of traditional Chinese medicine with modern technology to provide pain relief and promote healing (Chon et al., 2019). * Device: UNIPHY PHYACTION 740, made in EEC device. * Laser type: Gallium aluminum arsenide laser. * Wavelength: 808 nm. * Power Output: 200 mW. * Dose/energy density: 4J/point. * Frequency of treatment: Three times weekly for 8 weeks. * Duration: 12 min. * Cumulative dose: 48J/point. * Target Acupuncture Points: Key points for CTS: PC4 (Ximen), PC6 (Neiguan), PC7 (Daling), PC8 (Laogong), LI4 (Hegu), LI10 (Shousanli), LI11 (Quchi), HT-2 (Qingling), HT7 (Shenmen), HT-8 (Shaofu), LU9 (Taiyuan) and LU10 (Yuji)

Traditional Therapy: * Splinting/Bracing: Patients in the two groups will advised to wear a static wrist splint locked at 0\_ wrist flexion for at least 8 h at night throughout the entire length of the study as the primary management which reduce pressure on the median nerve. * Physical Therapy: Engaging in specific exercises, such as nerve glide exercises and wrist stretches, can improve mobility and reduce symptoms. These exercises aim to restore normal movement of the median nerve and alleviate compression

Study summary

The purpose of this study is to determine the efficacy of laser acupuncture in alleviating CTS symptoms following flexor tendon repair in the hand.

Eligibility

Sex
ALL
Min age
20 Years
Max age
40 Years
Healthy volunteers
No
Inclusion Criteria: * Adults aged 20-40 years who have undergone flexor tendon repair surgery. * Patients who have undergone primary or secondary repair of flexor tendons in the hand at zone 4 (zone of carpal tunnel as it often be complicated by postoperative adhesions due to close quarters and synovial sheath of the carpal tunnel) (Fulchignoni C et al., 2020). * Surgery occurred within a specific timeframe, often within 6-12 weeks prior to inclusion (Peters SE, Jha B, Ross M., 2021). * Patient have clinical and electro diagnostic evidence of CTS. * All patients enrolled to the study will have their informed consent. Exclusion Criteria: * Pre-existing neurological disorders. * Systemic illnesses affecting nerve function (e.g., diabetes). * Contraindications to laser therapy. * Pregnancy or breastfeeding. * Active infections or open wounds in the hand or wrist. * Previous history of carpal tunnel release surgery or received an injection of steroid for CTS. * Previous history of brachial plexus injury or median nerve injury. * Other severe neurological or musculoskeletal conditions. * Epilepsy or any psychological disorders. * Cancer. * Spots over the treated points. * Pacemaker or implanted devices.

Primary outcome measure(s)

  • Symptom Relief: — At baseline and after 8 weeks
    Measured by the Visual Analog Scale (VAS) for pain, numbness, and tingling.

Trial sites (1)

FacilityCityRegionStatus
Learning Hospitals Al Kaser Al Ayni Hospitals Cairo Egypt
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07014774 on ClinicalTrials.gov ↗ ← All trials in Egypt